๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Brachytherapy for pediatric tumors

โœ Scribed by Subir Nag; Douglas B Tippin


Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
176 KB
Volume
2
Category
Article
ISSN
1538-4721

No coin nor oath required. For personal study only.

โœฆ Synopsis


Purpose: Pediatric tumors are generally managed with a multi-modality treatment program that includes surgery, chemotherapy, and teletherapy. The use of teletherapy in young children can result in significant long-term toxicity (especially retardation of growth of bones and organs). The use of brachytherapy is an attractive alternative because brachytherapy irradiates small volumes and can thus potentially minimize complications.

Methods and Materials:

The brachytherapy techniques used are similar to those used in adults. Low-dose-rate brachytherapy with manually-afterloaded removable 192 Ir is commonly used though it is associated with some radiation exposure hazards. Low energy radionuclides and remote afterloading technology have been used to reduce the radiation exposure hazards. Teletherapy is often added in the treatment of more extensive tumors, especially in older children. Results: Brachytherapy (as the sole radiation modality) to small volumes in conjunction with chemotherapy and surgery has produced good local control with growth preservation and acceptable late complications in selected patients with localized tumors. Conclusion: Brachytherapy increases local control with a decrease in the probability of late complications (especially altered bone and organ growth) in comparison to EBRT. Low energy radionuclides and remote afterloading technology (HDR, IOHDR, and PDR) have been used to extend treatment to infants and younger children while reducing the radiation exposure to patients, family, and medical personnel.


๐Ÿ“œ SIMILAR VOLUMES


Brachytherapy for brain tumors
โœ Todd W. Vitaz; Peter C. Warnke; Viviane Tabar; Philip H. Gutin ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› Springer US ๐ŸŒ English โš– 279 KB
Intraoperative high-dose-rate brachyther
โœ Karyn A Goodman; Suzanne L Wolden; Michael P LaQuaglia; Kaled Alektiar; David D' ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 197 KB

Purpose: To evaluate the efficacy and toxicity of intraoperative high-dose-rate brachytherapy (IOHDR) in the management of pediatric solid tumors. ## Methods and Materials: The records of 66 pediatric patients who underwent IOHDR for a solid tumor from February 1993 through December 2002 were ret

Brachytherapy in pediatric oncology
โœ Quon, Harry ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 47 KB

{ Sylvain Baruchel is the Principal Investigator of an industry sponsored study (Schering-Plough). He receives no monetary compensation. Grant sponsor: Temodal 1 (the manufacturers of temozolomide), Schering Plough, Inc. (for the Phase I Clinical Trial).

Interstitial brachytherapy for metastati
โœ Michael Prados; Steve Leibel; Colleen M. Barnett; Philip Gutin ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 412 KB ๐Ÿ‘ 1 views
Interstitial brachytherapy procedures fo
โœ Penny K. Sneed; Michael W. McDermott; Philip H. Gutin ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 320 KB ๐Ÿ‘ 2 views

Promising results have been obtained using brachytherapy in the treatment of brain tumors. Very low-dose rate brachytherapy (60-100 Gy given at 0.05-0.10 Gy/h) has been used for low-grade gliomas, resulting in 5- and 10-year survival probabilities of 85% and 83% for pilocytic astrocytomas and 61% an

Interstitial brachytherapy for malignant
โœ Michael W. McDermott; Penny K. Sneed; Philip H. Gutin ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 59 KB ๐Ÿ‘ 2 views

For nearly 20 years, interstitial brachytherapy has been used as adjuvant treatment for malignant brain tumors in both prospective clinical trials and as part of standard therapy. Numerous publications analyzing the results of this treatment seem to indicate an improvement in median survival for hig